Dipeptidyl peptidase IV contributes to the pathogenesis of Cryptococcus neoformans
Abstract
We previously identified isoleucine–proline–isoleucine (IPI) as a small molecule associated with extracellular vesicles (EVs) in Cryptococcus . The administration of IPI in vivo resulted in the control of experimental cryptococcal infection through mechanisms that remain unknown. IPI is an inhibitor of dipeptidyl peptidase 4 (Dpp4), an enzyme that regulates insulin and glucose homeostasis in mammals and may also influence pathogenic processes in fungi. Based on these observations, we investigated the biological and pathogenic roles of cryptococcal Dpp4. We demonstrate that Cryptococcus neoformans synthesizes an active, surface-associated Dpp4 that is inhibited by IPI. Deletion of the Dpp4-encoding gene (CNAG_06416) abolished Dpp4 enzymatic activity and resulted in marked physiological alterations, including changes in the proteomic composition of whole cells and EVs, as well as increased accumulation of undivided cells at 37°C both in vitro and in vivo . The dpp4 Δ mutant was less lethal than wild-type (WT) cells in a Galleria mellonella infection model. In contrast, increased Dpp4 activity did not enhance lethality, as demonstrated by the ability of WT and 19 high-Dpp4-expressing mutant strains to kill G. mellonella . In a murine model, loss of Dpp4 partially affected fungal virulence, delaying host mortality, and reducing fungal burden, particularly in the brain. This finding is consistent with the observation that dpp4 Δ cells were markedly less efficient at crossing endothelial and extracellular matrix layers than WT cells. Collectively, these findings establish DPP4 as an important regulator of cryptococcal physiology and pathogenesis, and support the concept that targeting Dpp4 may offer translational opportunities distinct from conventional antifungal strategies. IMPORTANCE Cryptococcosis is a life-threatening fungal disease that mainly affects people with weakened immune systems, and current treatments remain limited. In this study, we show that the enzyme dipeptidyl peptidase 4 (Dpp4) plays a central role in the ability of the fungus to cause damage to the host. When Dpp4 is absent, the fungus becomes less virulent, disseminates less efficiently to the brain, and is less likely to kill the host. These findings reveal a previously unrecognized role for Dpp4 in fungal infection and identify this enzyme as a promising target for new therapeutic strategies. By focusing on a fungal pathway distinct from those targeted by existing drugs, this work opens new avenues for developing treatments against a major human fungal pathogen.
Related
- Host Metabolic Reprogramming Defines Macrophage Antifungal Activity Against Cryptococcus neoformans
- Absence of a spindle position checkpoint in the fungal pathogen Cryptococcus neoformans
- Therapeutic vulnerabilities of the drug-resistant fungal meningitis pathogen Cryptococcus neoformans
- Genomic hallmarks of parasexual reproduction in three hybrid groups of the human pathogen Cryptococcus neoformans
- Yck2 links mitochondrial function and pH homeostasis to cell wall remodeling and antifungal susceptibility in Cryptococcus neoformans
BibTeX
@article{reis2026dipeptidyl,
title = {{Dipeptidyl peptidase IV contributes to the pathogenesis of Cryptococcus neoformans}},
author = {Flavia Reis and Haroldo Oliveira and Daniel Zamith-Miranda and Debora Oliveira and Bárbara Bezerra and Nicolly Sensato and Cássia Souza and Juliana Rizzo and Lucas de O. Las Casas and Flora Bohner and Bianca Sena and Amanda Camillo-Andrade and Frédérique Moyrand and Marlon Santos and Paulo Carvalho and Guilhem Janbon and Joshua Nosanchuk and Marcio Rodrigues},
journal = {mBio},
year = {2026},
month = aug,
doi = {10.1128/mbio.01465-26},
url = {https://pasteur.hal.science/pasteur-05772357v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Dipeptidyl peptidase IV contributes to the pathogenesis of Cryptococcus neoformans
AU - Flavia Reis
AU - Haroldo Oliveira
AU - Daniel Zamith-Miranda
AU - Debora Oliveira
AU - Bárbara Bezerra
AU - Nicolly Sensato
AU - Cássia Souza
AU - Juliana Rizzo
AU - Lucas de O. Las Casas
AU - Flora Bohner
AU - Bianca Sena
AU - Amanda Camillo-Andrade
AU - Frédérique Moyrand
AU - Marlon Santos
AU - Paulo Carvalho
AU - Guilhem Janbon
AU - Joshua Nosanchuk
AU - Marcio Rodrigues
PY - 2026
DA - 2026/08/12
JO - mBio
DO - 10.1128/mbio.01465-26
UR - https://pasteur.hal.science/pasteur-05772357v1
AB - We previously identified isoleucine–proline–isoleucine (IPI) as a small molecule associated with extracellular vesicles (EVs) in Cryptococcus . The administration of IPI in vivo resulted in the control of experimental cryptococcal infection through mechanisms that remain unknown. IPI is an inhibitor of dipeptidyl peptidase 4 (Dpp4), an enzyme that regulates insulin and glucose homeostasis in mammals and may also influence pathogenic processes in fungi. Based on these observations, we investigated the biological and pathogenic roles of cryptococcal Dpp4. We demonstrate that Cryptococcus neoformans synthesizes an active, surface-associated Dpp4 that is inhibited by IPI. Deletion of the Dpp4-encoding gene (CNAG_06416) abolished Dpp4 enzymatic activity and resulted in marked physiological alterations, including changes in the proteomic composition of whole cells and EVs, as well as increased accumulation of undivided cells at 37°C both in vitro and in vivo . The dpp4 Δ mutant was less lethal than wild-type (WT) cells in a Galleria mellonella infection model. In contrast, increased Dpp4 activity did not enhance lethality, as demonstrated by the ability of WT and 19 high-Dpp4-expressing mutant strains to kill G. mellonella . In a murine model, loss of Dpp4 partially affected fungal virulence, delaying host mortality, and reducing fungal burden, particularly in the brain. This finding is consistent with the observation that dpp4 Δ cells were markedly less efficient at crossing endothelial and extracellular matrix layers than WT cells. Collectively, these findings establish DPP4 as an important regulator of cryptococcal physiology and pathogenesis, and support the concept that targeting Dpp4 may offer translational opportunities distinct from conventional antifungal strategies. IMPORTANCE Cryptococcosis is a life-threatening fungal disease that mainly affects people with weakened immune systems, and current treatments remain limited. In this study, we show that the enzyme dipeptidyl peptidase 4 (Dpp4) plays a central role in the ability of the fungus to cause damage to the host. When Dpp4 is absent, the fungus becomes less virulent, disseminates less efficiently to the brain, and is less likely to kill the host. These findings reveal a previously unrecognized role for Dpp4 in fungal infection and identify this enzyme as a promising target for new therapeutic strategies. By focusing on a fungal pathway distinct from those targeted by existing drugs, this work opens new avenues for developing treatments against a major human fungal pathogen.
SN - 2161-2129
SN - 2150-7511
ER -